New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20B
ABSTRACT The polysaccharide (PS) capsule of Streptococcus pneumoniae (pneumococcus) is the immunodominant surface structure that shields the bacteria from the host immune system. Since the capsule is the primary target of currently available pneumococcal vaccines, anti-capsular antibodies are highly...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2025-01-01
|
| Series: | Microbiology Spectrum |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/spectrum.02443-24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556078869872640 |
|---|---|
| author | Jigui Yu Neil Ravenscroft Peter Davey Roshan Liyanage Oliver Lorenz Michelle M. Kuttel Stephanie W. Lo Feroze A. Ganaie Moon H. Nahm |
| author_facet | Jigui Yu Neil Ravenscroft Peter Davey Roshan Liyanage Oliver Lorenz Michelle M. Kuttel Stephanie W. Lo Feroze A. Ganaie Moon H. Nahm |
| author_sort | Jigui Yu |
| collection | DOAJ |
| description | ABSTRACT The polysaccharide (PS) capsule of Streptococcus pneumoniae (pneumococcus) is the immunodominant surface structure that shields the bacteria from the host immune system. Since the capsule is the primary target of currently available pneumococcal vaccines, anti-capsular antibodies are highly protective but serotype-specific. Pneumococci may evade host or vaccine-induced immunity as a result of variation in capsule structure mediated via multiple mechanisms, such as the loss or gain of O-acetylation. Previous biochemical studies of serogroup 20 isolates have identified two subtypes—20A and 20B, whose capsule PS differs in the WhaF-mediated glucose side chain. Herein, we characterize a newly discovered capsule type, 20C, that differs from serotype 20B via the inactivation of capsule O-acetyltransferase gene, wciG. Structural analysis demonstrated that 20C and 20B share an identical repeat unit [→3)-α-D-GlcpNAc-[β-D-Galf-(1→4)][α-D-Glcp-(1→6)]-(1→P→6)-α-D-Glcp-(1→6)- β-D-Glcp-(1→3)-β-D-Galf 5,6Ac2-(1→3)-β-D-Glcp-(1→], except for the absence of WciG-mediated O-acetyl group at terminal galactofuranose (β-D-Galf). We confirmed that deletion of the wciG gene in a 20B strain resulted in the expression of the 20C capsule. Serotype 20C is serologically indistinguishable from the canonical 20A and 20B using conventional serotyping antibodies, but serogroup 20 subtypes can be distinguished by sequencing of cps genes—whaF, wciG, and wcjE. While genetic screening suggests 20C to be globally less prevalent, a new variant was identified which appears to have both wciG and whaF genes inactive, potentially indicating it to be a new serotype. Consequently, genome-based serotyping/bioinformatic tools must scrutinize all cps genes for mutations that might inactivate/modify cps-encoded enzymes, ensuring effective tracking of emerging capsule variants in response to ongoing vaccination efforts.IMPORTANCEStreptococcus pneumoniae (pneumococcus) is a significant human pathogen known for producing a wide array of antigenically and structurally diverse capsule types, a fact that poses a serious challenge to the effectiveness of vaccines targeting pneumococcal capsule polysaccharide (PS). Herein, we provide a comprehensive analysis-genetic, antigenic, and biochemical of a newly identified capsule type, 20C, which differs from the canonical serotype 20B due to the inactivation of the capsule O-acetyltransferase gene, wciG. Our findings highlight how pneumococci can alter their capsule PS structure and immunological characteristics through minor genetic modifications. Since the appearance of new capsule types can directly affect pneumococcal conjugate vaccine (PCV) implementation, a deeper understanding of capsule PS at the genetic, immunological, and biochemical levels is critical for the development of future diagnostic tools and vaccines. |
| format | Article |
| id | doaj-art-34fb78d6cc564d309afeb0c098e3a4dd |
| institution | Kabale University |
| issn | 2165-0497 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | Microbiology Spectrum |
| spelling | doaj-art-34fb78d6cc564d309afeb0c098e3a4dd2025-01-07T14:05:18ZengAmerican Society for MicrobiologyMicrobiology Spectrum2165-04972025-01-0113110.1128/spectrum.02443-24New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20BJigui Yu0Neil Ravenscroft1Peter Davey2Roshan Liyanage3Oliver Lorenz4Michelle M. Kuttel5Stephanie W. Lo6Feroze A. Ganaie7Moon H. Nahm8Department of Medicine, Division of Pulmonary/Allergy/Critical Care, University of Alabama at Birmingham, Birmingham, Alabama, USADepartment of Chemistry, University of Cape Town, Rondebosch, South AfricaVaxcyte, San Carlos, California, USAVaxcyte, San Carlos, California, USAParasites and Microbes, Wellcome Sanger Institute, Hinxton, Cambridge, United KingdomDepartment of Computer Science, University of Cape Town, Rondebosch, South AfricaParasites and Microbes, Wellcome Sanger Institute, Hinxton, Cambridge, United KingdomDepartment of Medicine, Division of Pulmonary/Allergy/Critical Care, University of Alabama at Birmingham, Birmingham, Alabama, USADepartment of Medicine, Division of Pulmonary/Allergy/Critical Care, University of Alabama at Birmingham, Birmingham, Alabama, USAABSTRACT The polysaccharide (PS) capsule of Streptococcus pneumoniae (pneumococcus) is the immunodominant surface structure that shields the bacteria from the host immune system. Since the capsule is the primary target of currently available pneumococcal vaccines, anti-capsular antibodies are highly protective but serotype-specific. Pneumococci may evade host or vaccine-induced immunity as a result of variation in capsule structure mediated via multiple mechanisms, such as the loss or gain of O-acetylation. Previous biochemical studies of serogroup 20 isolates have identified two subtypes—20A and 20B, whose capsule PS differs in the WhaF-mediated glucose side chain. Herein, we characterize a newly discovered capsule type, 20C, that differs from serotype 20B via the inactivation of capsule O-acetyltransferase gene, wciG. Structural analysis demonstrated that 20C and 20B share an identical repeat unit [→3)-α-D-GlcpNAc-[β-D-Galf-(1→4)][α-D-Glcp-(1→6)]-(1→P→6)-α-D-Glcp-(1→6)- β-D-Glcp-(1→3)-β-D-Galf 5,6Ac2-(1→3)-β-D-Glcp-(1→], except for the absence of WciG-mediated O-acetyl group at terminal galactofuranose (β-D-Galf). We confirmed that deletion of the wciG gene in a 20B strain resulted in the expression of the 20C capsule. Serotype 20C is serologically indistinguishable from the canonical 20A and 20B using conventional serotyping antibodies, but serogroup 20 subtypes can be distinguished by sequencing of cps genes—whaF, wciG, and wcjE. While genetic screening suggests 20C to be globally less prevalent, a new variant was identified which appears to have both wciG and whaF genes inactive, potentially indicating it to be a new serotype. Consequently, genome-based serotyping/bioinformatic tools must scrutinize all cps genes for mutations that might inactivate/modify cps-encoded enzymes, ensuring effective tracking of emerging capsule variants in response to ongoing vaccination efforts.IMPORTANCEStreptococcus pneumoniae (pneumococcus) is a significant human pathogen known for producing a wide array of antigenically and structurally diverse capsule types, a fact that poses a serious challenge to the effectiveness of vaccines targeting pneumococcal capsule polysaccharide (PS). Herein, we provide a comprehensive analysis-genetic, antigenic, and biochemical of a newly identified capsule type, 20C, which differs from the canonical serotype 20B due to the inactivation of the capsule O-acetyltransferase gene, wciG. Our findings highlight how pneumococci can alter their capsule PS structure and immunological characteristics through minor genetic modifications. Since the appearance of new capsule types can directly affect pneumococcal conjugate vaccine (PCV) implementation, a deeper understanding of capsule PS at the genetic, immunological, and biochemical levels is critical for the development of future diagnostic tools and vaccines.https://journals.asm.org/doi/10.1128/spectrum.02443-24Streptococcus pneumoniaecapsule polysaccharideserogroup 20O-acetyltransferasevaccine |
| spellingShingle | Jigui Yu Neil Ravenscroft Peter Davey Roshan Liyanage Oliver Lorenz Michelle M. Kuttel Stephanie W. Lo Feroze A. Ganaie Moon H. Nahm New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20B Microbiology Spectrum Streptococcus pneumoniae capsule polysaccharide serogroup 20 O-acetyltransferase vaccine |
| title | New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20B |
| title_full | New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20B |
| title_fullStr | New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20B |
| title_full_unstemmed | New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20B |
| title_short | New pneumococcal serotype 20C is a WciG O-acetyltransferase deficient variant of canonical serotype 20B |
| title_sort | new pneumococcal serotype 20c is a wcig o acetyltransferase deficient variant of canonical serotype 20b |
| topic | Streptococcus pneumoniae capsule polysaccharide serogroup 20 O-acetyltransferase vaccine |
| url | https://journals.asm.org/doi/10.1128/spectrum.02443-24 |
| work_keys_str_mv | AT jiguiyu newpneumococcalserotype20cisawcigoacetyltransferasedeficientvariantofcanonicalserotype20b AT neilravenscroft newpneumococcalserotype20cisawcigoacetyltransferasedeficientvariantofcanonicalserotype20b AT peterdavey newpneumococcalserotype20cisawcigoacetyltransferasedeficientvariantofcanonicalserotype20b AT roshanliyanage newpneumococcalserotype20cisawcigoacetyltransferasedeficientvariantofcanonicalserotype20b AT oliverlorenz newpneumococcalserotype20cisawcigoacetyltransferasedeficientvariantofcanonicalserotype20b AT michellemkuttel newpneumococcalserotype20cisawcigoacetyltransferasedeficientvariantofcanonicalserotype20b AT stephaniewlo newpneumococcalserotype20cisawcigoacetyltransferasedeficientvariantofcanonicalserotype20b AT ferozeaganaie newpneumococcalserotype20cisawcigoacetyltransferasedeficientvariantofcanonicalserotype20b AT moonhnahm newpneumococcalserotype20cisawcigoacetyltransferasedeficientvariantofcanonicalserotype20b |